Document is current
Any future updates will be listed below
-
Authors
Cappelli, Laura C.
Konig, Maximilian F.
Gelber, Allan C.
Bingham, Clifton O. III
Darrah, Erika
-
Funding
Funding for this research was provided by:
Office of the Secretary of Defense (W81XWH-15-1-0159)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR053503, AR070254)
Jerome L. Greene Foundation (Scholar Award, Scholar Award)
Camille Julia Morgan Arthritis Research and Education Fund
- License Information
-
More Information
Article History
Received: 2 November 2017
Accepted: 1 February 2018
First Online: 23 March 2018
Ethics approval and consent to participate
: The Johns Hopkins Institutional Review Board has approved this study and all participants signed informed consent forms (IRB #: NA-00040493; NA-00071923).
: Not applicable.
: ED previously served on the scientific advisory board for Padlock Therapeutics, Inc., and is an author on licensed Patent No. 8,975,033 entitled “Human Autoantibodies Specific for PAD3 which are Cross-reactive with PAD4 and their Use in the Diagnosis and Treatment of Rheumatoid Arthritis and Related Diseases”. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
